Menu Search
Equities

argenx SE

ARGX:BRU

argenx SE

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)582.60
  • Today's Change17.80 / 3.15%
  • Shares traded74.86k
  • 1 Year change+29.61%
  • Beta0.5556
Data delayed at least 15 minutes, as of Nov 22 2024 16:39 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy4
Outperform13
Hold2
Sell0
Strong Sell1

Share price forecast in USD

The 17 analysts offering 12 month price targets for argenx SE have a median target of 607.20, with a high estimate of 688.16 and a low estimate of 156.86. The median estimate represents a 4.22% increase from the last price of 582.60.
High18.1%688.16
Med4.2%607.20
Low-73.1%156.86

Dividends

Dividend information is not available for argenx SE.
Div growth (TTM)--
More ▼

Earnings history & estimates in USD

On Oct 31, 2024, argenx SE reported 3rd quarter 2024 earnings of 1.39 per share. This result exceeded the 0.01 consensus of the 13 analysts covering the company and outperformed last year's 3rd quarter results by 2.64.
The next earnings announcement is expected on Feb 27, 2025.
Average growth rate+70.86%
argenx SE reported annual 2023 losses of -5.16 per share on Feb 29, 2024.
Average growth rate-40.29%
More ▼

Revenue history & estimates in USD

argenx SE had 3rd quarter 2024 revenues of 588.88m. This bettered the 539.41m consensus of the 18 analysts covering the company. This was 156.30% above the prior year's 3rd quarter results.
Average growth rate+15.16%
argenx SE had revenues for the full year 2023 of 1.27bn. This was 184.91% above the prior year's results.
Average growth rate+211.28%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.